Organization
Astex Pharmaceuticals
18 clinical trials
Clinical trial
An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical StudiesStatus: Terminated, Estimated PCD: 2021-10-04
Clinical trial
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid NeoplasmsStatus: Terminated, Estimated PCD: 2023-02-20
Clinical trial
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)Status: Completed, Estimated PCD: 2021-07-31
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating AgentsStatus: Completed, Estimated PCD: 2020-03-31
Clinical trial
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Status: Terminated, Estimated PCD: 2022-01-14
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid LeukemiaStatus: Completed, Estimated PCD: 2020-01-20
Clinical trial
A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination With Venetoclax in Adult Patients With Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination With All-Trans Retinoic Acid (ATRA) in Subjects With Relapsed or Refractory (r/r) Acute Myeloid Leukemia (AML)Status: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic ImpairmentStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal FunctionStatus: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase 2 Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab for Previously Untreated Subjects With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)Status: Terminated, Estimated PCD: 2023-08-21
Clinical trial
An Open-Label, Multicenter, Extension Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study CentersStatus: , Estimated PCD: 2024-12-31
Clinical trial
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)Status: Recruiting, Estimated PCD: 2025-12-01